IBRX as reported
ImmunityBio, Inc. reported $166M of revenue over the trailing twelve months, +193% on the year before. 9 reported series are charted on this page, each one as filed.
$166M
Revenue, trailing twelve months · to Q2 2026 · +193% against the twelve months before
- Net Income
- −$992M
Net Income · +170% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$288M
Free Cash Flow · −19% year on year · trailing twelve months to Q2 2026
- Op Margin
- −155%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $166M | +193% | Q2 2026 |
| Net Income | −$992M | +170% | Q2 2026 |
| EPS | −$0.97 | +102% | Q2 2026 |
| Gross Margin | 99% | n/a | Q2 2026 |
| Op Margin | −155% | n/a | Q2 2026 |
| Net Margin | −563% | n/a | Q2 2026 |
| ROE | 82% | n/a | Q2 2026 |
| ROA | −107% | n/a | Q2 2026 |
| Free Cash Flow | −$288M | −19% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
ImmunityBio, Inc. (IBRX) - Revenue & ProfitRevenue & ProfitImmunityBio, Inc. (IBRX)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com